In reviewing the therapeutic category of blood modifiers, there are 3 areas of focus
Todd Cooperman, PharmD, RPh
Advertisement
Articles by Todd Cooperman, PharmD, RPh
Advertisement
Latest Updated Articles
- Therapy Class Review: Blood Modifiers
Published: March 2nd 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5